The potential therapeutic effects and future value of Daprodustat in addition to conventional indications

Daprodustat (Daprodustat) is a HIF-PH (hypoxia-inducible factor -prolyl hydroxylase) inhibitor. Its current core indications are mainly focused on chronic kidney disease-related anemia. However, judging from its mechanism of action, it not only promotes the stable expression of endogenous erythropoietin (EPO), but also involves multiple biological pathways such as iron metabolism regulation, cell metabolism changes, anti-inflammation and tissue repair, so it is considered to have potential wider therapeutic value. Researchers are trying to evaluate its feasibility in diseases other than hematopoietic disorders and lay a theoretical foundation for future expansion of indications.

One of the most interesting potential directions is its possible value in inflammatory diseases. As a HIF pathway regulator, daprostat can affect cells' oxygen utilization efficiency and regulate signaling pathways related to inflammatory response to a certain extent. Some scholars have suggested that HIF stabilizers may play an auxiliary role in certain chronic inflammatory states, inflammatory bowel disease or microcirculatory disorders-related diseases, but related research is still in the early stages. Due to the clear metabolic characteristics and drug interactions of daprostat, it is also regarded as one of the candidates that can be further developed into anti-inflammatory or microenvironment-improving drugs.

Additionally, daprostat's potential use in cardiovascular and microvascular diseases is also being discussed. Its characteristics of promoting red blood cell production and improving tissue oxygen supply make it theoretically possible to be used to improve some hypoxia-related diseases, such as chronic heart failure, peripheral vascular disease or tissue hypoxia in certain metabolic diseases. Although there is currently no definite clinical evidence to support this promotion, early experimental data suggest that the HIF pathway may play a certain role in myocardial protection, angiogenesis and repair, so daprostat is expected to participate in cardiovascular research in the future.

Finally, daplestat is also expected to have certain potential in the research of metabolic diseases other than kidney disease. HIF Regulation is closely related to glucose metabolism, lipid metabolism and mitochondrial function, so related research is exploring the possibility of its application in metabolic syndrome, diabetic complications and even tissue regenerative medicine. However, these prospects are still in the basic research or animal testing stage, and it will take a long time to verify the expansion of real clinical indications. Therefore, judging from the current evidence, the future application value of daprostat is worth looking forward to, but a large number of high-quality studies are still needed to further confirm its safety and effectiveness.

Keyword tags:

Daprostat,HIF-PHI, potential therapeutic effect, future value, inflammatory diseases, cardiovascular diseases, metabolic diseases

Reference materials:https://www.ncbi.nlm.nih.gov/